Barbara V Howard1, Jacques E Rossouw. 1. aMedStar Health Research Institute, Hyattsville, Maryland bGeorgetown-Howard Universities Center for Clinical and Translational Science, Washington, District of Columbia cNational Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: In 2002 and 2004, the Women's Health Initiative found no evidence that hormone therapy with estrogen or estrogen with progestin (E + P) protected against cardiovascular disease (CVD). Since then, further analyses have been performed. This review summarizes current analyses on the effects of hormone therapy on CVD and CVD risk factors. RECENT FINDINGS: The negative effects of hormone therapy vary by the type of CVD event. Estrogen alone and E + P show consistent effects on CVD, but E + P has more impact on coronary heart disease (CHD) and venous thromboembolism. Women of all ethnicities, including those who are obese, have diabetes, or are taking daily aspirin or statins remain at risk for adverse effects from hormone therapy. Although younger women or more recently menopausal women taking hormone therapy may be at relatively lower risk for CHD and myocardial infarction, they remain at risk for stroke, venous thromboembolism and peripheral artery disease. Adverse effects are enhanced in older women with menopausal symptoms. Although hormone therapy lowers LDL cholesterol and lipoprotein (a) and raises high-density lipoprotein cholesterol, it has adverse effects on triglyceride, lipoprotein composition, and inflammatory and hemostatic markers. Baseline metabolic syndrome and high LDL cholesterol increase the CHD risk with hormone therapy. Analyses of discontinuation data in the estrogen-alone and E + P trials suggest that the adverse effects of hormone therapy on CVD are reversible. SUMMARY: Recent analyses do not justify postmenopausal hormone therapy for CVD prevention. Further research on the role of hormone therapy-induced changes in CVD risk factors along with genetic studies may increase understanding and aid in developing safer therapies for menopausal symptoms.
PURPOSE OF REVIEW: In 2002 and 2004, the Women's Health Initiative found no evidence that hormone therapy with estrogen or estrogen with progestin (E + P) protected against cardiovascular disease (CVD). Since then, further analyses have been performed. This review summarizes current analyses on the effects of hormone therapy on CVD and CVD risk factors. RECENT FINDINGS: The negative effects of hormone therapy vary by the type of CVD event. Estrogen alone and E + P show consistent effects on CVD, but E + P has more impact on coronary heart disease (CHD) and venous thromboembolism. Women of all ethnicities, including those who are obese, have diabetes, or are taking daily aspirin or statins remain at risk for adverse effects from hormone therapy. Although younger women or more recently menopausal women taking hormone therapy may be at relatively lower risk for CHD and myocardial infarction, they remain at risk for stroke, venous thromboembolism and peripheral artery disease. Adverse effects are enhanced in older women with menopausal symptoms. Although hormone therapy lowers LDL cholesterol and lipoprotein (a) and raises high-density lipoprotein cholesterol, it has adverse effects on triglyceride, lipoprotein composition, and inflammatory and hemostatic markers. Baseline metabolic syndrome and high LDL cholesterol increase the CHD risk with hormone therapy. Analyses of discontinuation data in the estrogen-alone and E + P trials suggest that the adverse effects of hormone therapy on CVD are reversible. SUMMARY: Recent analyses do not justify postmenopausal hormone therapy for CVD prevention. Further research on the role of hormone therapy-induced changes in CVD risk factors along with genetic studies may increase understanding and aid in developing safer therapies for menopausal symptoms.
Authors: Judith Hsia; Michael H Criqui; David M Herrington; Joann E Manson; Lieling Wu; Susan R Heckbert; Matthew Allison; Mary McGrae McDermott; Jennifer Robinson; Kamal Masaki Journal: Am Heart J Date: 2006-07 Impact factor: 4.749
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick Journal: JAMA Date: 2007-04-04 Impact factor: 56.272
Authors: Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Charles Kooperberg; Mary Cushman; Judith Hsia; Jennifer G Robinson; Aaron K Aragaki; John K Lynch; Alison E Baird; Karen C Johnson; Lewis H Kuller; Shirley A A Beresford; Beatriz Rodriguez Journal: PLoS Clin Trials Date: 2007-06-15
Authors: M S McLaughlin; P J Hinckley; S M Treiman; S-E Kim; G J Stoddard; D L Parker; G S Treiman; J S McNally Journal: AJNR Am J Neuroradiol Date: 2015-09-03 Impact factor: 3.825